Engineered Virus, 16/68,830, No. 1-4-US-160688300FP1 (U.S. Pat. App. Oct. 16, 2018)

Form PTO- 1449 (modified)
`
`Atty. Docket N0.:
`KEMP.P0086US/1001036775
`
`Page 1 of 4
`Serial N0.:
`
`16/068,830
`
`
`List of Patents and Publications for Applicant’s
`
`Applicant:
`
`REPLIMUNE LIMITED
`
`
`
`
`July 09, 2018
`(Use several sheets if necessary)
`
`
`Foreign Patent Documents
`U.S. Patent Documents
`See Pages 2-3
`See Pages 1-2
`
`
`
`INFORMATION DISCLOSURE STATEMENT
`
`
`
`
`
`Not Yet Assigned
`Other Art
`See Pages 3-4
`
`
`
`
`Exam.
`Init.
`
`Ref.
`Des.
`
`Document
`Number
`
`U.S. Patent Documents
`
`5,122,458
`
`06/16/92
`
`5,168,062
`
`12/01/92
`
`5,288,641
`
`02/22/94
`
`5,328,688
`
`07/12/94
`
`5,385,839
`
`01/31/95
`
`5,599,691
`
`02/04/97
`
`5,602,007
`
`02/11/97
`
`5,698,531
`
`5,824,318
`
`5,846,707
`
`12/16/97
`
`10/20/98
`
`12/08/98
`
`6,040,169
`
`03/21/00
`
`A10
`
`A11
`
`Name
`
`Post et 31.
`
`Stinski
`
`Roizman
`
`Roizman
`
`Stinski
`
`Roizman
`
`Dunn et 31.
`
`Nabel et 211.
`
`Mohr et 31.
`
`Roizman
`
`Brown et 31.
`
`Roizman
`
`A12
`
`A13
`
`A14
`
`A15
`
`A16
`
`A17
`
`A18
`
`A19
`
`A20
`
`A21
`
`A22
`
`A23
`
`6,071,692
`
`06/06/00
`
`6,120,773
`
`09/19/00
`
`6,172,047
`
`01/09/01
`
`6,297,219
`
`10/02/01
`
`6,340,673
`
`01/22/02
`
`6,423,528
`
`07/23/02
`
`Roizman
`
`Roizman et 31.
`
`Nabel et 31.
`
`Roizman et 31.
`
`Brown et 31.
`
`6,428,968
`
`08/06/02
`
`Molnar-Kimber et 31.
`
`6,649,157
`
`11/18/03
`
`6,770,274
`
`08/03/04
`
`7,063,835
`
`06/20/06
`
`7,223,593
`
`05/29/07
`
`7,537,924
`
`05/56/09
`
`Coffey et 31.
`
`Martuza et 31.
`
`Coffin
`
`Coffin
`
`Coffin
`
`735526211
`
`EXAMINER:
`
`DATE CONSIDERED:
`
`
`
`EXAMINER: INITIAL IF REFERENCE CONSIDERED, WI- *THER OR NOT CITATION IS IN CONFORMANCE WITH WEP609; DRAW LINE THROUGH
`CITATION IF NOT IN CONFORMANCE AND NOT CONSIDE (ED. INCLUDE COPY OF THIS FORM WITH NEXT COMTVIUNICATION TO APPLICANT.
`
`
`INFORMATION DISCLOSURE STATEMENT 7 PTO-1 4 49 (MODIFIED)
`
`

`Page 2 of 4
`Serial N0.:
`
`Atty. Docket N0.:
`
`Form PTO- 1449 (modified)
`KEMP.P0086US/1001036775
`16/068,830
`
`
`
`List of Patents and Publications for Applicant’s
`
`Applicant:
`
`REPLIMUNE LIMITED
`
`
`
`
`July 09, 2018
`(Use several sheets if necessary)
`
`
`Foreign Patent Documents
`U.S. Patent Documents
`See Pages 2-3
`See Pages 1-2
`
`
`
`INFORMATION DISCLOSURE STATEMENT
`
`
`
`
`Not Yet Assigned
`
`Other Art
`See Pages 3-4
`
`
`
`
`Exam.
`Init.
`
`Ref.
`Des.
`
`Document
`Number
`
`U.S. Patent Documents
`
`A24
`
`A25
`
`A26
`
`A27
`
`A28
`
`A29
`
`A30
`
`7,749,745
`
`07/06/10
`
`7,981,669
`
`07/19/11
`
`8,273,568
`
`09/25/12
`
`8,277,818
`
`10/02/12
`
`8,361,978
`
`01/29/13
`
`8,470,577
`
`06/25/13
`
`8,679,830
`
`03/25/14
`
`8,703,120
`
`04/22/14
`
`A32
`
`8,680,068
`
`03/25/ 14
`
`10/28/14
`
`Name
`
`Johnson et 31.
`
`Coffin et 31.
`
`Martuza et 31.
`
`Coffin
`
`Rabkin et 31.
`
`Johnson et 31.
`
`Coffin et 31.
`
`Martuza et 31.
`
`Coffin
`
`Johnson et 31.
`
`A33
`
`A34
`
`A35
`
`A36
`
`A37
`
`A38
`
`A39
`
`A40
`
`A41
`
`8,871,193
`
`9,827,307
`
`11/28/17
`
`8,986,672
`
`03/24/15
`
`10,039,796
`
`2008/0014175
`
`08/07/18
`
`01/17/08
`
`2010/0297072
`
`11/25/ 10
`
`2014/0154216
`
`06/05/14
`
`2014/0271677
`
`09/18/14
`
`2015/0232812
`
`08/20/15
`
`Rabkin et 31.
`
`Zhang et 31.
`
`Zhang et 31.
`
`Hallahan et 31.
`
`DePinho
`
`Coffin
`
`Palese et 31.
`
`Coffin
`
`Foreign Patent Documents
`
`Ref.
`Des.
`
`Document
`Number
`
`Country
`
`Bl
`
`WO 2006/0023 94
`
`01/05/06
`
`WIPO
`
`Language
`
`English
`
`Exam.
`Init.
`
`735526211
`
`EXAMINER:
`
`DATE CONSIDERED:
`
`
`
`EXAMINER: INITIAL IF REFERENCE CONSIDERED, WI- *THER OR NOT CITATION IS IN CONFORMANCE WITH WEP609; DRAW LINE THROUGH
`CITATION IF NOT IN CONFORMANCE AND NOT CONSIDE (ED. INCLUDE COPY OF THIS FORM WITH NEXT COMTVIUNICATION TO APPLICANT.
`
`
`INFORMATION DISCLOSURE STATEMENT 7 PTO-1 4 49 (MODIFIED)
`
`

`Page 3 of 4
`
`Serial No.:
`
`Atty. Docket No.:
`Form PTO- 1449 (modified)
`KEMP.P0086US/1001036775
`16/068,830
`
`
`
`REPLIMUNE LIMITED
`
`List of Patents and Publications for Applicant’s
`
`Applicant:
`
`INFORMATION DISCLOSURE STATEMENT
`
`(Use several sheets if necessary)
`U.S. Patent Documents
`See Pages 1-2
`
`
`
`Filing Date:
`July 09, 2018
`Foreign Patent Documents
`See Pages 2-3
`
`Exam.
`Init.
`
`Ref.
`Des.
`
`Foreign Patent Documents
`Document
`Number
`
`Country
`
`132
`
`B3
`
`B4
`
`135
`
`B7
`
`B8
`
`WO 2007/123737
`
`11/01/07
`
`WO 2014/066532
`
`05/01/14
`
`W0 97/ 12623
`
`04/10/97
`
`WO 2014/022138
`
`02/06/14
`
`WO 2014/036412
`
`03/06/14
`
`WO 2016/008976
`
`01/21/16
`
`WO 2017/118866
`
`07/13/17
`
`WIPO
`
`WIPO
`
`WIPO
`
`WIPO
`
`WIPO
`
`WIPO
`
`WIPO
`
`
`
`
`Group:
`Not Yet Assigned
`
`Other Art
`See Pages 3-4
`
`
`
`
`Language
`
`English
`
`English
`
`English
`
`English
`
`English
`
`English
`
`English
`
`Other Art (Including Author, Title, Date Pertinent Pages, Etc.)
`Ref.
`Citation
`Des.
`
`Exam.
`Init.
`
`0 _
`
`0N
`
`U.)
`
`0.p
`
`0u:
`
`0ox
`
`Chou et al., “Mapping of Herpes Simplex Virus-1 Neurovirulence to «(134.5, a Gene
`Nonessential for Growth in Culture,” Science, 1990, 250(4985):1262-1266
`
`Du et al., “Tumor-specific oncolytic adenoviruses expressing granulocyte macrophage colony-
`stimulating factor or anti-CTLA4 antibody for the treatment of cancers,” Cancer Gene Therapy,
`2014, 21(8):340-348.
`
`Gangi et al., “The safety of talimogene laherparepvec for the treatment of advanced
`melanoma,” Expert Opinion on Drug Safety, 2016, pages 1-5.
`
`Gibney et al., “Preliminary results from a phase 1/2 study of INCB024360 combined with
`ipilimumab (ipi) in patients (pts) with melanoma.” 2014 ASCO Annual Meeting, No. 3010.
`
`International Search Report and Written Opinion issued in International Patent Application No.
`PCT/GB2017/050038, dated April 24, 2017.
`
`Liu et al., “ICP34.5 deleted herpes simplex cirus with enhanced oncolytic, immune stimulating,
`and anti-tumour properties,” Gene Therapy, 2003, 10(4):292-303
`
`735526211
`
`EXAMINER:
`
`DATE CONSIDERED:
`
`
`
`EXAMINER: INITIAL IF REFERENCE CONSIDERED, WI- aTI-IER OR NOT CITATION IS IN CONFORMANCE WITH WEP609; DRAW LINE THROUGH
`CITATION IF NOT IN CONFORMANCE AND NOT CONSIDE (ED. INCLUDE COPY OF THIS FORM WITH NEXT COMIVIUNICATION TO APPLICANT.
`
`
`INFORMATION DISCLOSURE STATEMENT 7 PTO-1 4 49 (MODIFIED)
`
`

`Form PTO- 1449 (modified)
`
`Atty. Docket N0.:
`KEMP.P0086US/1001036775
`
`Page 4 of 4
`
`Serial N0.:
`16/068,830
`
`
`List of Patents and Publications for Applicant’s
`
`Applicant:
`
`REPLIMUNE LIMITED
`
`
`
`
`July 09, 2018
`(Use several sheets if necessary)
`
`
`Foreign Patent Documents
`U.S. Patent Documents
` See Pages 2-3 See Pages 1-2
`
`
`
`INFORMATION DISCLOSURE STATEMENT
`
`
`
`
`Not Yet Assigned
`
`Other Art
`See Pages 3-4
`
`
`
`
`Other Art (Including Author, Title, Date Pertinent Pages, Etc.)
`Ref.
`Citation
`Des.
`
`Exam.
`Init.
`
`0
`
`0
`
`0
`
`\ooo\1
`
`C10
`
`C11
`
`C12
`
`C13
`
`C1 4
`
`Maclean eta1., “Herpes simplex cirus type 1 deletion variants 1714 and 1716 pinpoint
`neurovirulence-related sequences in Glasgow strain 17 + between immediate early gene 1 and
`the ‘a’ sequence,” Journal of General Virology, 1991, 72:631-639
`
`Piasecki et al, “Talilmogene laherparepvec increases the anti-tumor efficacy of the anti-PD-l
`immune checkpoint blockade,” AACR Annual Meeting Presentation Abstract, April 19, 2015.
`
`Reese, “Abstract IA24: New frontiers in oncolytic virus therapy,” Cancer Immunology
`Research, 2016, 4(11):1A24-1A24.
`
`Robinson et al, “Novel Imrnunocompetent Murine Tumor Model for Evaluation of
`Conditionally Replication-Competent (Oncolytic) Murine Adenoviral Vectors,” Journal of
`Virology, 2009, 83(8):3450-3462.
`
`Senzer eta1., “Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor-
`Encoding, Second-Generation Oncolytic herpesvirus in Patients with Unresectable Metastatic
`Melanoma” Journal ofClinical Oncology, 2009, 27(34):5763-5771.
`
`Simpson et al, “Combination of a Fusogenic Glycoprotein, Prodrug activation, and Oncolytic
`Herpes Simplex Virus for Enhanced Local Tumor Control,” Cancer Research, 2006,
`66(9):4835-4842.
`
`Sokolowski et al., “Oncolytic virotherapy using herpes simplex virus: how far have we come?”
`Oncolytic Virotherapy, 2015, 4:207-219.
`
`Yan et al., “Developing Novel Oncolytic Adenoviruses through Bioselection,” Journal of
`Virology, 2003, 77(4):2640-2650.
`
`735526211
`
`EXAMINER:
`
`DATE CONSIDERED:
`
`
`
`EXAMINER: INITIAL IF REFERENCE CONSIDERED, Wl- *THER OR NOT CITATION IS IN CONFORMANCE WITH WEP609; DRAW LINE THROUGH
`CITATION IF NOT IN CONFORMANCE AND NOT CONSIDE (ED. INCLUDE COPY OF THIS FORM WITH NEXT COMTVIUNICATION TO APPLICANT.
`
`
`INFORMATION DISCLOSURE STATEMENT 7 PTO-1 4 49 (MODIFIED)
`
`

This document is available on Docket Alarm but you must sign up to view it.

Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

Up-to-date information for this case.
Email alerts whenever there is an update.
Full text search for other cases.
Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.

Access Government Site

We are redirecting you
to a mobile optimized page.

Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket

Supplemental Search

Search for PTAB Motions

PTAB Analytics

TTAB Analytics

Basic Search

Filters

Party Search

Advanced

Selected Courts

Recently Selected Courts

Find PTAB Decisions

PTAB Analytics

Special PTAB Alerts

Orange Book

Directly Search Federal Courts

Search Trademark ...

This document is available on Docket Alarm but you must sign up to view it.

Accessing this document will incur an additional charge of $.

Still Working On It

A few More Minutes ... Still Working

This document could not be displayed.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

One Moment Please

Your document is on its way!

Sealed Document

We are redirecting youto a mobile optimized page.

Document Unreadable or Corrupt

We are unable to display this document.

STEP 2 of 2

Choose your membership type

Flat-Fee

Pay-As-You-Go Monthly

Add your payment information

Login or Join

Enter your corporate Email

Thousands of your peers are saving time and gaining a competitive advantage with Docket Alarm.

Join Docket Alarm to perform smarter legal research.

Download this document and millions of others instantly with a Docket Alarm membership.

Join Docket Alarm and start performing smarter legal research.

Start tracking this docket instantly with a Docket Alarm membership.

Join thousands of your peers and start performing smarter legal research.

STEP 1 of 2

Millions of Documents | 15 Seconds to Signup

Hi !

Welcome to Docket Alarm

Welcome to Docket Alarm!

Explore Litigation Insights andManage Your Cases

Reset Password

What is PACER?

Why do I need it?

What will I be charged?

Do other courts have fees?

Basic Free Access

Welcome

Thank you

Check Firm Account

We are redirecting you
to a mobile optimized page.

Explore Litigation Insights and
Manage Your Cases